Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine

Vaccine

Volumn 24, Issue 26, 2006, Pages 5498-5508

  He, Yuxian ^a   Li, Jingjing ^a   Du, Lanying ^b   Yan, Xuxia ^a   Hu, Guangan ^b   Zhou, Yusen ^b   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Epitopes; Neutralizing antibodies; Receptor binding domain; SARS CoV

Indexed keywords

EPITOPE; INACTIVATED VACCINE; MONOCLONAL ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS SPIKE PROTEIN; VITRONECTIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RECEPTOR BINDING; SARS CORONAVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; EPITOPES; MEMBRANE GLYCOPROTEINS; MICE; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 33744827401     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.054     Document Type: Article

References (42)

1. Drosten C., Gunther S., Preiser W., van der W.S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1967-1976
2. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1953-1966
3. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
4. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
5. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
6. Cyranoski D., and Abbott A. Virus detectives seek source of SARS in China's wild animals. Nature 423 6939 (2003) 467
7. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 5643 (2003) 276-278
8. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102 39 (2005) 14040-14045
9. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
10. He Y., and Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol 18 2 (2005) 327-332
11. Jiang S., He Y., and Liu S. SARS vaccine development. Emerg Infect Dis 11 7 (2005) 1016-1020
12. Marshall E., and Enserink M. Medicine caution urged on SARS vaccines. Science 303 5660 (2004) 944-946
13. Qin E., Shi H., Tang L., Wang C., Chang G., Ding Z., et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine (2005)
14. Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24 5 (2006) 652-661
15. Tang L., Zhu Q., Qin E., Yu M., Ding Z., Shi H., et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 23 6 (2004) 391-394
16. Xiong S., Wang Y.F., Zhang M.Y., Liu X.J., Zhang C.H., Liu S.S., et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 95 2 (2004) 139-143
17. Zhang C.H., Lu J.H., Wang Y.F., Zheng H.Y., Xiong S., Zhang M.Y., et al. Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain. Vaccine 23 24 (2005) 3196-3201
18. Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S.Y., et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23 24 (2005) 3202-3209
19. Zakhartchouk A.N., Liu Q., Petric M., and Babiuk L.A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23 35 (2005) 4385-4391
20. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 17 (2004) 6641-6646
21. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101 26 (2004) 9804-9809
22. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
23. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., et al. Recombinant modified vaccinia virus ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79 5 (2005) 2678-2688
24. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
25. Dimitrov D.S. The secret life of ACE2 as a receptor for the SARS virus. Cell 115 6 (2003) 652-653
26. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 6965 (2003) 450-454
27. Prabakaran P., Xiao X., and Dimitrov D.S. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 314 1 (2004) 235-241
28. Babcock G.J., Esshaki D.J., Thomas Jr. W.D., and Ambrosino D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78 9 (2004) 4552-4560
29. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279 5 (2004) 3197-3201
30. Xiao X., Chakraborti S., Dimitrov A.S., Gramatikoff K., and Dimitrov D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 312 4 (2003) 1159-1164
31. He Y., Zhou Y., Wu H., Luo B., Chen J., Li W., et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 173 6 (2004) 4050-4057
32. He Y., Zhu Q., Liu S., Zhou Y., Yang B., Li J., et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334 1 (2005) 74-82
33. Zhou T., Wang H., Luo D., Rowe T., Wang Z., Hogan R.J., et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 78 13 (2004) 7217-7226
34. He Y., Lu H., Siddiqui P., Zhou Y., and Jiang S. Receptor-binding domain of SARS coronavirus spike protein contains multiple conformational-dependant epitopes that induce highly potent neutralizing antibodies. J Immunol 174 8 (2005) 4908-4915
35. He Y., Zhou Y., Siddiqui P., and Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 325 2 (2004) 445-452
36. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 17 (2006) 3624-3631
37. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324 2 (2004) 773-781
38. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 5742 (2005) 1864-1868
39. Qu X.X., Hao P., Song X.J., Jiang S.M., Liu Y.X., Wang P.G., et al. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem 280 33 (2005) 29588-29595
40. Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24 8 (2005) 1634-1643
41. Yi C.E., Ba L., Zhang L., Ho D.D., and Chen Z. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol 79 18 (2005) 11638-11646
42. Chakraborti S., Prabakaran P., Xiao X., and Dimitrov D.S. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2 (2005) 73